Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 11, 2022
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
[ Fri, Mar 11th 2022
] - WOPRAI
Anupam Rama Maintained (BBIO) at Buy with Decreased Target to $18 on, Mar 11th, 2022
Anupam Rama of JP Morgan, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Decreased Target from $21 to $18 on, Mar 11th, 2022.
Anupam has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Anupam's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Anupam
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $26 on, Wednesday, March 9th, 2022
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $24 on, Tuesday, December 28th, 2021
